Pfizer Stops Epilepsy Drug Trial as Efficacy Proved

Pfizer Inc., the world’s biggest drugmaker, said it stopped a clinical trial of its epilepsy medicine Lyrica after results showed it was as effective as a stand-alone therapy for certain-types of seizures.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.